Luis Ferbeyre, MD

Dr. Luis Ferbeyre, MD, serves as Chief Medical Officer at Immunocine and has been a cornerstone of the organization since its inception. As a board-trained oncologist and seasoned clinical leader, he is responsible for ensuring that every patient considered for Immunocine’s therapies receives care that is safe, ethical, evidence-based, and individualized.

Dr. Ferbeyre earned his medical degree from the Medical University of Havana and pursued specialized training in Oncology, with his thesis focused on mixed tumors of the salivary glands. He continued advanced oncology studies with a focus on cervicofacial cancers at the University of Paris and head and neck cancer at the National Institute of Oncology and Radiology, building deep expertise in complex and aggressive malignancies.

A prolific researcher, Dr. Ferbeyre has authored 31 peer-reviewed publications exploring the genetic and molecular foundations of cancer, as well as the application of reconstructive oncologic surgery in head and neck malignancies. He has also participated in multiple clinical trials, reinforcing his commitment to advancing cancer care through rigorous scientific inquiry.

At Immunocine, Dr. Ferbeyre oversees comprehensive medical reviews to evaluate patient eligibility and guide treatment strategy, always prioritizing patient safety and clinical appropriateness. His role often includes integrating complementary or synergistic treatment options—such as chemotherapy, immune checkpoint inhibitors, or other evidence-supported therapies—when they meaningfully enhance patient outcomes.

Known for his direct yet deeply compassionate approach, Dr. Ferbeyre brings clarity and calm to some of the most difficult conversations patients face. His ability to explain complex medical realities with honesty, humility, and even humor helps patients feel grounded and empowered throughout their journey. He is unwaveringly transparent, always placing truth and patient welfare above optimism without substance.

Above all, Dr. Ferbeyre is guided by a singular mission: to help cancer patients ethically and responsibly access innovative treatment approaches that may improve their chances—whether or not those paths ultimately involve Immunocine. When Immunocine is not the best fit, he remains committed to offering thoughtful, well-reasoned recommendations to support patients wherever their care continues.

Dr. Ferbeyre is a member of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). Through his blend of scientific rigor, moral clarity, and genuine humanity, he embodies Immunocine’s commitment to putting patients first—always.